Submitted:
17 November 2026
Posted:
18 November 2026
You are already at the latest version
Abstract
Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited prognostic biomarkers after curative-intent resection. We aim to determine if loss of SMAD4 protein expression has prognostic significance in operated PDAC patients. Methods: SMAD4 protein expression was evaluated by immunohistochemistry (IHC) in resected PDAC tu-mours from patients treated at two centers. The prognostic significance of SMAD4 expression status and clinical outcomes, namely overall survival (OS) and recurrence-free survival (RFS), was assessed using survival analysis with Kaplan–Meier estimation and Cox proportional hazards regression models. Results: A total of 87 patients with resected PDAC were included in the final analysis, with a median follow-up of 75.9 months. In univariable analysis, SMAD4 expression status was not associated with OS (intact vs. lost: HR = 0.87, p = 0.56) or RFS (HR = 0.84, p = 0.51). In multivariable analysis, SMAD4 expression was not an independent prognostic factor for OS (HR = 0.94, p = 0.81) or RFS (HR = 0.82, p = 0.49). Established clinicopathological variables, including histological grade, nodal status, postoperative CA19-9 levels, and adju-vant treatment, were independently associated with both survival outcomes, while resection status was inde-pendently associated with OS. Conclusions: In this bicentric cohort, loss of SMAD4 expression assessed by IHC was not an independent prognostic marker for OS or RFS of resected PDAC. Despite the potential SMAD4 relevance within specific biological or clinical subgroups, further studies are warranted to clarify the role of SMAD4 in PDAC risk strati-fication and support the development of integrated molecular and clinicopathological prognostic models.
Keywords:
biomarker
; prognosis
; overall survival
; pancreatic cancer
; recurrence-free survival
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.